Results 261 to 270 of about 8,164,322 (359)

DRUG UTILIZATION STUDY OF BENZODIAZEPINES BASED ON WHO CORE DRUG USE INDICATORS IN AN OUTPATIENT DEPARTMENT OF A TERTIARY CARE HOSPITAL IN EASTERN UTTAR PRADESH, INDIA

JAYANT RAI, A.C. Pandey, Jamal Haider, Shashank Mishra   +3 more
openalex   +2 more sources

Combining antibody conjugates with cytotoxic and immune‐stimulating payloads maximizes anti‐cancer activity

Molecular Oncology, EarlyView.
Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang, Dong Jun Koo, Peter M. Tessier, Greg M. Thurber   +3 more
wiley   +1 more source

Changes in nationwide thyroid hormone replacement use during the pandemic: results from the Trends in Drug Utilization During COVID-19 Pandemic in Turkey (PANDUTI-TR) Study. [PDF]

Naunyn Schmiedebergs Arch Pharmacol
Vizdiklar C, Aydin V, Gultekin O, Tazegul G, Akici A.   +4 more
europepmc   +1 more source

Dammarenediol II enhances etoposide‐induced apoptosis by targeting O‐GlcNAc transferase and Akt/GSK3β/mTOR signaling in liver cancer

Molecular Oncology, EarlyView.
Etoposide induces DNA damage, activating p53‐dependent apoptosis via caspase‐3/7, which cleaves PARP1. Dammarenediol II enhances this apoptotic pathway by suppressing O‐GlcNAc transferase activity, further decreasing O‐GlcNAcylation. The reduction in O‐GlcNAc levels boosts p53‐driven apoptosis and influences the Akt/GSK3β/mTOR signaling pathway ...
Jaehoon Lee, Byung‐Cheol Han, Gi‐Bang Koo, Jihye Park, Mijin Kwon, Young Bin Park, Jae‐Mun Choi, Seung‐Ho Lee, Sangho Roh   +8 more
wiley   +1 more source

Drug utilization pattern of romosozumab and other osteoporosis treatments in Japan, 2019-2021. [PDF]

J Bone Miner Metab
Soen S, Wang A, Hamaya E, Chien HC, Lin TC.   +4 more
europepmc   +1 more source

Drug Utilization Pattern In Dermatology: A Comprehensive Analysis Of Prescription Trends And Patient Management In Dermatological Outpatient Department

Asida Mohamed Ashraf, Reshmi Subramaniam, Revathi Rajkumar, L Manju   +3 more
openalex   +2 more sources

The PI3Kδ inhibitor roginolisib (IOA‐244) preserves T‐cell function and activity

Molecular Oncology, EarlyView.
Identification of novel PI3K inhibitors with limited immune‐related adverse effects is highly sought after. We found that roginolisib and idelalisib inhibit chronic lymphocytic leukemia (CLL) cells and Treg suppressive functions to similar extents, but roginolisib affects cytotoxic T‐cell function and promotion of pro‐inflammatory T helper subsets to a
Elise Solli, Alessio Bevilacqua, Mathias Wenes, Denis Migliorini, Lars van der Veen, Sigrid S Skånland, Giusy Di Conza, Kjetil Taskén   +7 more
wiley   +1 more source

Editorial: Biologic drugs in immune-mediated inflammatory diseases, validation, drug-utilization, effectiveness, regulation, costs, and safety in the real-world. [PDF]

Front Pharmacol
Convertino I, Lopes LC, Pratt N, Ingrasciotta Y, Tuccori M.   +4 more
europepmc   +1 more source

Evaluation of Drug Utilization Pattern Among Adult Patients in A District Headquarters Government Hospital Using World Health Organization Indicators

R. Vigneswaran, Prashant Natarajan, Saravana Kumar R, E Jeniba, V Kaviya, P Pasupathy   +5 more
openalex   +1 more source

Targeting p38α in cancer: challenges, opportunities, and emerging strategies

Molecular Oncology, EarlyView.
p38α normally regulates cellular stress responses and homeostasis and suppresses malignant transformation. In cancer, however, p38α is co‐opted to drive context‐dependent proliferation and dissemination. p38α also supports key functions in cells of the tumor microenvironment, including fibroblasts, myeloid cells, and T lymphocytes.
Angel R. Nebreda
wiley   +1 more source